Category: Articles

Catalyst’s Plan for Amifampridine phosphate® NDA

Robert Gadimian from www.hotbiotechstocks.com explains Catalyst’s plan for amifampridine phosphate NDA in Lambert-Eaton Myasthenic Syndrome (LEMS). Introduction Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) focuses on developing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Their main compound is amifampridine phosphate. Amifampridine phosphate® is…

Catalyst A Great Come Back Story

Introduction Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) focuses on developing innovative therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Their main compound is Firdapse® (amifampridine phosphate). Firdapse® is being studied in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), and Myasthenia Gravis patients with…

How Does Nabriva Compare To Paratek?

Introduction Nabriva is developing a novel first-in class antibiotic for Community-Acquired Bacterial Pneumonia (CABP). Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is the second use they are aiming for. Let’s look at Nabriva’s investment case considering Paratek compound (omadacycline) which also targets CABP and…